1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA on COVID-19: 'Fast-Tracking Does Not Mean Cutting Corners'

Agency Insists Safety And Efficacy Are Paramount

 
• By Ian Schofield

EMA advises caution on COVID-19 vaccine timelines, but says the outlook is more promising for new treatments.  

EU_Flag_Covid19
The EU's regulator explains its outlook on COVID-19 drug and vaccine development • Source: Shutterstock

The first treatments for COVID-19 could be granted a marketing authorization in the EU as soon as the summer if clinical trial results are positive, but a vaccine is unlikely to be available for another year, according to top executives at the European Medicines Agency.

Using fast-track mechanisms to speed up the development of coronavirus therapeutics and vaccines did not equate to “cutting corners” with regard to safety and efficacy testing, the executives said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.